Cost, coverage and availability
[US] Oncologists have complained that many patients cannot afford the "astronomical" cost of $138,000 a year, which makes it one of the most expensive drugs in medicine, and [in their view] far more expensive than what is needed to pay the development costs.In 2015 ponatinib is available in England for the treatment of CML (chronic phase, accelerated phase or blast phase) and Ph+ ALL in patients with documented T315I mutation under the Cancer Drugs Fund, and has not been appraised by the National Institute for Health and Care Excellence (NICE), who noted the small expected patient population. NICE estimated that ponatinib would cost approximately £61,000 per year, but the price paid under the Cancer Drugs Fund is confidential and may be different. See also
Bcr-Abl tyrosine-kinase inhibitor, especially the sections on Ponatinib development
 and binding

References
External links
"Ponatinib". Drug Information Portal. U.S. National Library of Medicine.
An allergic transfusion reaction is when a blood transfusion results in allergic reaction. It is among the most common transfusion reactions to occur. Reported rates depend on the degree of active surveillance versus passing reporting to the blood bank. Overall, they are estimated to complicate up to 3% of all transfusions. The incidence of allergic transfusion reactions is associated with the amount of plasma in the product. More than 90% of these reactions occur during transfusion. Signs and symptoms
Cause
Allergic reactions from blood transfusion may occur from the presence of allergy-causing antigens within the donors blood, or transfusion of antibodies from a donor who has allergies, followed by antigen exposure.An allergic transfusion reaction is a type of transfusion reaction that is defined according to the Center for Disease Control (CDC)  as:

Diagnosis
An allergic transfusion reaction is diagnosed if two or more of the following occur within 4 hours of cessation of transfusion:

A probable diagnosis results if any one of the following occurring within 4 hours of cessation of transfusion:
The UK hemovigilance reporting system (SHOT), has classified allergic reactions in to mild, moderate and severe. Reactions can occur that have features of both allergic and febrile reactions. Mild
A rash, urticaria, or flushing

Moderate
Wheeze (bronchospasm) or angioedema but blood pressure normal and no respiratory compromise. There may or may not be an associated rash or urticaria. Severe
This can be due to:
Severe breathing problems (Bronchospasm, stridor), angioedema, or circulatory problems (e.g. hypotension) which require immediate medical treatment OR admission to hospital OR lengthens the duration of hospital admission.